Competition intensifying for diabetes subjects; Acurian Acurian, a company that specializes in patient recruiting, has reached a significant business milestone with the addition of more than 50 percent of the country’s type 2 diabetes population to its database. Approximately 8 million of the estimated 16 million diagnosed type 2 or adult-onset diabetes are already on … Read more
Sun Pharma eyes tie-ups in Europe DRUG major Sun Pharmaceuticals Industries Ltd is looking for partnerships in the European market to fuel its next level of growth in the international arena. The company, however, has dropped its plans to raise funds of about $350 million through a foreign currency convertible bond issue. To support the … Read more
FDA lists drugs with potential safety issues A list of drugs currently being evaluated for potential safety issues by the US Food and Drug Administration (FDA) has been posted on its website. The list has been published under laws brought in last September that require the FDA to inform the public of new safety information or potential … Read more
Sandoz boosts Canadian production capacity Sandoz Canada, a unit of Novartis’ generics arm, has opened a second manufacturing plant at its site in Boucherville, Quebec, boosting local production capacity 66 per cent. The plant, which is due to be fully operational by mid September, comprises manufacturing, laboratory and warehousing space that the firm believes will … Read more
Cholesterol- lowering drug given cancer all-clear Cancer fears about a cholesterol- lowering drug have turned out to be a ‘statistical blip’. A class of cholesterol- lowering drug that had been implicated in a cancer scare has been cleared by epidemiologists using the results from two large ongoing clinical trials. Preliminary results from the relatively small … Read more
Big pharma’s pre-competitive collaboration Merck, Eli Lilly and Pfizer have provided funding to launch Enlight Biosciences, a for-profit venture that aims to advance breakthrough technologies for drug discovery and development. The lowdown: There has recently been increasing emphasis from industry on participating in non-profit collaborations to address issues in drug development that are considered to … Read more
